IP Library › Granted Patent US 11,760,741
Granted Patent B2
US 11,760,741 · App. 17/052,062 · Granted Sep 19, 2023

Pro-drugs of eliglustat

Inventors: Parva Yogeshchandra Purohit (Ahmedabad, IN); Pathik Subhashchandra Brahmkshatriya (Ahmedabad, IN)
Assignee: KASHIV BIOSCIENCES, LLC
C07D319/18C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,760,741
App. No.
17/052,062
Granted
Sep 19, 2023
Kind
B2
Abstract

The present invention is directed to pro-drugs of Eliglustat (formula A) and process for the preparation thereof. The present invention is further directed to pharmaceutical composition thereof and method of treatment using the same.

Claims (61)

1. A compound of formula A:

the geometric isomer, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof,

wherein R is selected from group consisting of:

a)

wherein, R 1 is selected from group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, cycloheteroalkyl, amine, alkoxy, carboxylic acid, alkyl substituted with cycloheteroalkyl; alkyl substituted amine, alkyl substituted carboxylic acid, alkene substituted carboxylic acid;

b)

wherein, R 2 is

or

wherein m and p are independently selected from 0 to 3, n is selected from less than 10, about 50, about 100, about 150 or about 200 and Z is alkyl or amine;

c) R 3 wherein, R 3 is selected from group consisting of boron species;

d)

wherein, R 4 is selected from group consisting of alkyl substituted with cycloheteroalkyl, optionally substituted with phosphoryl, alkyl substituted phosphoryl, sulfuryl, sulfonamide; and

e)

wherein, R 5 is selected from group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, cycloheteroalkyl, alkyl, amine, alkoxy, carboxylic acid, alkyl substituted with cycloheteroalkyl, alkyl substituted amine.

2. The compound of formula A according to claim 1 , which is represented by the following formula I:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein, R 1 is selected from group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, cycloheteroalkyl, amine, alkoxy, carboxylic acid, alkyl substituted with cycloheteroalkyl, alkyl substituted amine, alkyl substituted carboxylic acid, alkene substituted carboxylic acid.

3. The compound of formula A according to claim 1 , which is represented by the following formula II:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 2 is

wherein m and p are independently selected from 0 to 3, n is selected from less than 10, about 50, about 100, about 150 or about 200 and Z is alkyl or amine.

4. The compound of formula A according to claim 1 , which is represented by the following formula III:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 3 is selected from group consisting of boron species.

5. The compound of formula A according to claim 1 , which is represented by the following formula IV:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 4 is selected from group consisting of alkyl substituted with cycloheteroalkyl, optionally substituted phosphoryl, alkyl substituted phosphoryl, sulfuryl, sulfonamide.

6. The compound of formula A according to claim 1 , which is represented by the following formula IX:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 5 is selected from group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, cycloheteroalkyl, alkyl, amine, alkoxy, carboxylic acid, alkyl substituted with cycloheteroalkyl, alkyl substituted amine.

7. The compound of formula A according to claim 1 , represented by the following formula:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 1 is selected from group consisting of:

8. The compound of formula A according to claim 1 , represented by the following formula II:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 2 is selected from group consisting of:

9. The compound of formula A according to claim 1 , represented by the following formula III:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein, R 3 is selected from group consisting of:

10. The compound of formula A according to claim 1 , represented by the following formula IV:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 4 is selected from group consisting of:

11. The compound of formula A according to claim 1 , represented by the following formula IX:

the geometric isomers, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof;

wherein R 5 is selected from group consisting of:

12. A compound selected from group consisting of

or pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising compound of formula A represented by following structural formula:

the geometric isomer, enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof; and a pharmaceutically acceptable carrier or an excipient, wherein:

R is selected from group consisting of:

a)

wherein, R 1 is selected from group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, cycloheteroalkyl, amine, alkoxy, carboxylic acid, alkyl substituted with cycloheteroalkyl; alkyl substituted amine, alkyl substituted carboxylic acid, alkene substituted carboxylic acid;

b)

wherein, R 2 is

or

wherein m and p are independently selected from 0 to 3, n is selected from less than 10, about 50, about 100, about 150 or about 200 and Z is alkyl or amine;

c) R 3 wherein, R 3 is selected from group consisting of boron species;

d)

wherein, R 4 is selected from group consisting of alkyl substituted with cycloheteroalkyl, optionally substituted phosphoryl, alkyl substituted phosphoryl, sulfuryl, sulfonamide; and

e)

wherein, R 5 is selected from group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, cycloheteroalkyl, alkyl, amine, alkoxy, carboxylic acid, alkyl substituted with cycloheteroalkyl; alkyl substituted amine.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: KASHIV BIOSCIENCES, LLC
To: SHIVANKA RESEARCH, LLC
Reel/Frame 071115/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: SHIVANKA RESEARCH, LLC
To: AMNEAL PHARMACEUTICALS LLC
Reel/Frame 071115/0600 →
SHORT FORM TERM LOAN INTELLECTUAL PROPERTY ASSIGNMENT Recorded May 1, 2025
From: KASHIV BIOSCIENCES, LLC
To: ACQUIOM AGENCY SERVICES LLC, AS COLLATERAL AGENT
Reel/Frame 071150/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2021
From: PUROHIT, PARVA YOGESHCHANDRA; BRAHMKSHATRIYA, PATHIK SUBHASHCHANDRA
To: KASHIV BIOSCIENCES, LLC
Reel/Frame 055201/0719 →
Priority Claims (1)
IN 201821016626 · May 2, 2018 · national
Continuity (1)
Related Publication 20210300887A1 · Sep 30, 2021